Finding New Uses for Existing Anti-Tuberculosis Drugs
Author Information
Author(s): Lee Dongwoo, Islam Md Ataul, Natarajan Sathishkumar, Dudekula Dawood Babu, Chung Hoyong, Park Junhyung, Oh Bermseok, Rizvi Arshad, Gupta Yash
Primary Institution: Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea
Hypothesis
Can machine learning and molecular docking identify existing FDA-approved drugs that can be repurposed to target DNA Gyrase A and PknB for tuberculosis treatment?
Conclusion
The study successfully identified several FDA-approved drugs with potential efficacy against tuberculosis by targeting GyrA and PknB.
Supporting Evidence
- Six promising compounds were identified for GyrA and PknB, including DB11753 and DB14703, which showed potential for both targets.
- The study integrated various computational techniques to enhance the drug discovery process.
- Drug repurposing can significantly reduce the time and cost associated with developing new treatments.
Takeaway
Researchers used computer techniques to find old medicines that might work against tuberculosis, which is a serious disease. They found some promising candidates that could help treat it.
Methodology
The study used similarity searches, molecular docking, machine learning for binding affinity calculations, and molecular dynamics simulations to identify potential drug candidates.
Limitations
The study primarily focused on computational methods and did not include experimental validation of the identified drug candidates.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website